The word “compounded” used to come up mainly in conversations between pharmacists, physicians, and patients with unusual medical needs. Then GLP-1 medications became difficult to find, telehealth advertisements appeared everywhere, and compounding entered the public vocabulary almost overnight.
For someone trying to lose weight, the difference can seem mostly financial. An FDA-approved injection may cost hundreds of dollars more each month, while an online company offers what appears to be the same medication at a fraction of the price.
The advertisements often look reassuring. The product may be described as “compounded semaglutide,” “personalized tirzepatide,” or a formula containing semaglutide with vitamin B12. Some companies use photographs and colors that resemble familiar prescription brands.
That can leave patients with a reasonable question: if both products contain semaglutide, how different can they really be?
Potentially, quite different.
Compounded medications have a legitimate place in healthcare. Pharmacists make them every day for patients who cannot use an available commercial product. But a compounded medicine is not an FDA-approved drug, and it is not automatically equivalent to a brand-name or generic medication.
The distinction affects how the product is tested, manufactured, labelled, prescribed, and monitored. With injectable GLP-1 medications, it can also affect how confidently a patient knows what is in the vial and how much should be injected.
What is a compounded medication?
Compounding means preparing a medication for a particular medical need by combining, mixing, diluting, or changing ingredients.
Consider a child who needs a drug that is available only as a tablet but cannot swallow pills. A compounding pharmacist may prepare a liquid version. A patient allergic to a dye or filler in a commercial tablet might need a capsule made without that ingredient. Someone requiring an uncommon strength may also benefit from an individually prepared dose.
These are not loopholes or fringe uses. They are exactly why pharmacy compounding exists.
Compounding can also help during a genuine drug shortage. If an FDA-approved medicine becomes unavailable and meets the relevant legal conditions, qualified pharmacies or outsourcing facilities may temporarily produce compounded versions to keep patients from losing access to treatment.
That is what happened when demand for semaglutide and tirzepatide overwhelmed supply. Ozempic, Wegovy, Mounjaro, and Zepbound became household names, yet many patients could not reliably fill their prescriptions. Compounding expanded to fill part of that gap.
The shortage was real. So was the need.
What followed was more complicated. Compounded GLP-1 treatment grew from a shortage response into a large direct-to-consumer industry. Even after supplies of approved products improved, advertisements for inexpensive “generic” or “same ingredient” injections continued appearing online.
That language can blur a boundary that patients deserve to see clearly.
Compounded does not mean generic
This is probably the most common misunderstanding.
A generic medicine is FDA-approved. Its manufacturer must demonstrate that it meets regulatory standards and performs in the body in a way considered therapeutically equivalent to the reference brand-name drug.
A compounded medicine is not an FDA-approved generic.
The FDA does not review each compounded formula before it reaches patients. The agency has not independently confirmed that the finished product has the expected strength, remains stable for the stated period, produces the claimed clinical result, or is manufactured consistently from one batch to the next.
That does not mean every compounded medication is unsafe. It means the evidence and oversight are different.
A careful pharmacist preparing a dye-free capsule for one patient is not the same as a manufacturer producing millions of approved tablets. The first product answers an individual need. The second goes through a formal approval and manufacturing system designed for large-scale distribution.
Problems arise when compounded medications are promoted as though they have completed that same process.
Words such as “generic Ozempic” or “the same as Wegovy” may sound convenient, but there is no FDA-approved generic version of those branded drugs. A compounded semaglutide product should not be marketed as if it were one.
What FDA approval actually adds
FDA approval does not mean a medicine is free of side effects. Ozempic, Wegovy, Mounjaro, and Zepbound can all cause adverse reactions even when manufactured and used correctly.
Approval means that regulators have evaluated evidence for a specific product, dose, formulation, manufacturing process, and medical use. That process normally includes clinical studies, chemistry and manufacturing data, stability testing, inspection requirements, standardized labeling, and continued safety monitoring after approval.
Approved injectable GLP-1 products also arrive in established devices or presentations with defined concentrations. Patients receive dosing instructions designed around those specific products.
Compounded versions may come in multidose vials, prefilled syringes, or packaging that varies between pharmacies. The concentration may also differ.
One pharmacy might prepare a vial containing one concentration of semaglutide. Another might dispense a stronger formula and give completely different instructions. The patient may be told to inject a certain number of “units,” even though the prescription is written in milligrams.
That is where a seemingly small difference becomes clinically meaningful.
The dosing problem with compounded GLP-1 injections
A typical patient does not think in milligrams per milliliter. They think in terms of the line they need to reach on a syringe.
Now imagine that the patient changes telehealth providers. The new vial contains a different concentration, but the syringe looks similar. Last month, the correct dose may have been 20 units. This month, 20 units could deliver considerably more medication.
The number on the syringe did not change. The amount of drug did.
The FDA has received reports involving patients and healthcare professionals who made mistakes when converting between milligrams, milliliters, and syringe units. Some people injected five or ten times the intended amount. Reported consequences have included severe nausea, vomiting, abdominal pain, dehydration, fainting, pancreatitis, and gallstones. Certain patients needed hospital care.
These cases do not prove that every compounded GLP-1 vial will be dosed incorrectly. They show how easily an error can happen when concentrations, containers, and instructions are not standardized.
A prefilled branded pen removes much of the measuring process. A multidose vial places more responsibility on the patient to draw up the correct volume.
Someone comfortable using syringes may find that straightforward. Someone injecting a medication for the first time may not.
If a compounded medicine is prescribed, the pharmacist should physically or visually demonstrate the dose. The patient should be able to answer four questions before the first injection:
- What is my dose in milligrams?
- What is the concentration inside this particular vial?
- How many milliliters or syringe units should I inject?
- Will those instructions change when I receive my next vial?
“Take as directed” is not enough when a mistake can multiply the intended dose several times over.
Are compounded GLP-1 medications still legal?
The short answer is that compounding remains legal, but mass-producing copies of commercially available GLP-1 drugs is much more restricted now that the shortages have been resolved.
Semaglutide injections were removed from the FDA shortage list in February 2025. The tirzepatide shortage had been declared resolved earlier. During transition periods, the FDA allowed compounders additional time to adjust their operations and avoid abruptly interrupting patient care.
In April 2026, the agency again clarified that routine production of products considered “essentially copies” of available approved drugs does not qualify for the same shortage-related flexibility.
That does not mean every individually compounded prescription became illegal overnight.
Under Section 503A of federal law, a state-licensed pharmacy or physician may compound a medication for an identified patient with a valid prescription when the legal requirements are met. Limited compounding may also be possible when the prescriber determines that a change creates a significant clinical difference for that particular patient.
The key word is particular.
Adding vitamin B12 to semaglutide for every customer is not automatically individualized care. Offering unusual doses simply because they are cheaper or easier to market does not necessarily establish a medical need. A genuine clinical difference should relate to the patient—not to a company’s business model.
Section 503B outsourcing facilities operate under a different framework. They register with the FDA, are subject to current good manufacturing practice requirements, and may produce larger quantities under specified conditions. Registration still does not turn their products into FDA-approved medicines.
In April 2026, the FDA proposed excluding semaglutide, tirzepatide, and liraglutide from the list of bulk substances that 503B facilities may use based on clinical need. At the time of that proposal, the FDA said it had not identified sufficient clinical need to include them. That was a proposed regulatory step, not the approval of a new compounded product category.
The practical message for patients is simple: the phrase “doctor prescribed” does not answer every legal or quality question. Ask why the compounded product is being used instead of an available FDA-approved option and which facility actually prepared it.
What are 503A and 503B pharmacies?
These numbers sound technical, but the difference is useful.
A 503A compounding pharmacy typically makes a medication for an individual patient based on a prescription. Oversight largely occurs through state boards of pharmacy, although federal requirements still apply.
A 503B outsourcing facility can compound larger quantities for healthcare settings under specific conditions. These facilities register with the FDA, follow current good manufacturing practice standards, and are inspected according to a risk-based schedule.
Neither category means that the resulting medication is FDA-approved.
A 503B facility may operate under stricter federal manufacturing requirements than a traditional 503A pharmacy, but the FDA has still not approved each compounded drug for safety and effectiveness.
When a telehealth company sends a vial, the company name on the website may not be the name of the pharmacy that prepared it. The prescriber, marketing platform, dispensing pharmacy, and ingredient supplier can be separate businesses.
Patients should be told who is responsible for each part.
The ingredients may not be exactly what you expect
Approved Ozempic and Wegovy contain the base form of semaglutide used in their evaluated formulations. The FDA has warned that some compounded products may instead use semaglutide sodium or semaglutide acetate.
Those are salt forms of the compound. They are not the same active ingredient used in the approved products, and the FDA has said it is unaware of a lawful basis for using these salt forms in compounding. The agency also lacks information establishing that they have the same chemical and pharmacological properties as approved semaglutide.
This is not a minor naming difference.
A website may use “semaglutide” throughout its sales page while offering very little information about the substance supplied to the compounding pharmacy. Before paying, ask whether the formula contains semaglutide base or a salt form.
Another warning sign is the phrase “research use only” or “not for human consumption” attached to a product that is clearly being sold with human dosing instructions. Peptides purchased from chemical suppliers are not an appropriate substitute for prescription medication.
The same caution applies to retatrutide and cagrilintide. These investigational drugs are not FDA-approved, and the FDA states that they cannot legally be used in compounding under federal law. Retatrutide has produced attention because of promising weight-loss trial results, but promising research does not convert an experimental molecule into an approved pharmacy product. Our guide to retatrutide for weight loss explains where the research stands without treating the drug as commercially approved therapy.
Quality depends on more than the active ingredient
Even when a vial contains the expected ingredient, other details affect safety.
Sterile injections must be prepared in controlled conditions. Contamination with bacteria or fungi can lead to serious infection. The medication also needs the correct concentration, appropriate storage, reliable shipping, and a defensible beyond-use date.
Temperature is particularly relevant for injectable GLP-1 medications. The FDA has received complaints about compounded products arriving warm or with inadequate cooling materials.
A package sitting in the sun outside an apartment building is not merely inconvenient. Heat exposure may affect product quality. If an injectable medication arrives warm when it should have remained refrigerated, do not assume that putting it in the refrigerator restores it.
Call the dispensing pharmacy and ask what to do.
Patients using an online pharmacy should also be able to identify the licensed pharmacy, reach a pharmacist, receive clear instructions, and verify how the medicine will be shipped. A website that accepts payment without requiring a prescription or medical screening is not offering convenience; it is removing basic safeguards.
Compounding is not the villain
It would be unfair—and medically inaccurate—to portray all compounding as dangerous.
A skilled compounding pharmacist can solve problems that ordinary commercial products cannot. For certain patients, a custom liquid, dye-free capsule, topical formula, or unusual strength may be the only practical way to receive treatment.
The concern is unnecessary compounding.
When an FDA-approved medicine can meet a patient’s needs, replacing it with an unapproved imitation introduces extra uncertainty. That uncertainty may involve potency, sterility, labeling, stability, or the source of the active ingredient.
Cost is a real part of this conversation. Telling patients simply to purchase the more expensive product ignores why compounded GLP-1s became popular. Insurance exclusions and high out-of-pocket prices can make approved treatment unreachable.
Still, lower cost does not make two products medically equivalent. A patient deserves an honest discussion about both access and risk—not advertising that quietly erases the difference.
Questions to ask before using a compounded medication
A legitimate prescriber or pharmacist should not become defensive when asked basic questions.
Start with these:
- Why is a compounded medicine being recommended instead of an FDA-approved option?
- What patient-specific need does the compounded formula address?
- Which pharmacy or outsourcing facility prepared it?
- Is that facility licensed in my state?
- Is it a 503A pharmacy or a 503B outsourcing facility?
- What is the exact active ingredient?
- Does compounded semaglutide contain the base form or a salt?
- What is the concentration in milligrams per milliliter?
- How does that concentration translate into syringe units?
- How should the medicine be stored and transported?
- What should I do if it arrives warm?
- Who can I call if the label, dose, or appearance changes?
- How are side effects and quality problems reported?
Also look at the prescription label. It should identify the dispensing pharmacy and provide usable directions. Misspelled words, missing contact information, damaged packaging, or a pharmacy address that cannot be verified deserve attention.
The FDA has reported fraudulent compounded semaglutide and tirzepatide labels, including cases where the named pharmacy did not exist or had not made the product.
That is a reason to verify—not a reason to panic.
When to seek medical help
Nausea, constipation, diarrhea, and reduced appetite can occur with both approved and compounded GLP-1 medicines. Symptoms become more concerning when they are severe, persistent, or appear after a possible dosing mistake.
Contact the prescriber promptly if you cannot keep fluids down, repeatedly vomit, feel faint, or suspect that you injected the wrong volume.
Severe abdominal pain—particularly pain that reaches the back—may require urgent assessment. So may signs of dehydration, confusion, very low blood sugar, an allergic reaction, or symptoms of gallbladder disease.
Do not try to “cancel out” an excessive dose at home. Semaglutide remains in the body for a long time, so monitoring and supportive treatment may be needed.
Changes that seem unrelated can also deserve attention. Rapid weight loss, reduced protein intake, and nutritional deficiencies may contribute to shedding in some patients. Our pharmacist-reviewed discussion of whether Ozempic can cause hair loss looks at that connection in more detail.
What should current compounded-GLP-1 patients do?
Do not abruptly stop a prescribed medication because of a frightening headline.
Start by finding out exactly what you are receiving. Look at the label, contact the dispensing pharmacy, and ask the prescriber why the compounded version remains appropriate now that approved products are commercially available.
Some patients may have a documented medical reason for a customized preparation. Others may discover that the product was selected mainly because of price or because the telehealth company built its program around compounded medication.
The next step will not be identical for everyone. It may involve continuing temporarily under professional supervision, changing the formulation, moving to an approved medication, adjusting the dose, or discussing a different weight-management plan.
What should not happen is passive renewal of a vial nobody can clearly explain.
Approved and compounded medicines can both come from pharmacies. Both can be prescribed by clinicians. Both may contain a familiar-sounding ingredient.
They are still not interchangeable categories.
Compounding is personalized preparation intended to meet a medical need. FDA approval is a formal review of a specific drug product supported by evidence, manufacturing controls, and standardized labeling. One does not substitute for the other simply because an advertisement uses the same molecule’s name.
That distinction is not designed to frighten patients away from pharmacists. It is there to help them ask better questions before the next package arrives.
